- Home
- MRCC vs INBX Comparison
MRCC vs INBX Comparison
Compare MRCC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- INBX
- Stock Information
- Founded
- MRCC 2011
- INBX 2010
- Country
- MRCC United States
- INBX United States
- Employees
- MRCC N/A
- INBX N/A
- Industry
- MRCC Investment Managers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- INBX Health Care
- Exchange
- MRCC Nasdaq
- INBX Nasdaq
- Market Cap
- MRCC 174.8M
- INBX 218.9M
- IPO Year
- MRCC 2012
- INBX 2020
- Fundamental
- Price
- MRCC $8.24
- INBX $12.74
- Analyst Decision
- MRCC Strong Buy
- INBX Hold
- Analyst Count
- MRCC 1
- INBX 1
- Target Price
- MRCC $9.00
- INBX N/A
- AVG Volume (30 Days)
- MRCC 65.9K
- INBX 74.4K
- Earning Date
- MRCC 11-12-2024
- INBX 11-14-2024
- Dividend Yield
- MRCC 12.14%
- INBX N/A
- EPS Growth
- MRCC 298.01
- INBX N/A
- EPS
- MRCC 0.60
- INBX 119.38
- Revenue
- MRCC $62,007,000.00
- INBX $1,568,000.00
- Revenue This Year
- MRCC N/A
- INBX N/A
- Revenue Next Year
- MRCC N/A
- INBX N/A
- P/E Ratio
- MRCC $13.73
- INBX $0.11
- Revenue Growth
- MRCC N/A
- INBX 19.24
- 52 Week Low
- MRCC $6.97
- INBX $10.80
- 52 Week High
- MRCC $8.80
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- MRCC 46.26
- INBX 32.23
- Support Level
- MRCC $8.10
- INBX $13.57
- Resistance Level
- MRCC $8.80
- INBX $16.83
- Average True Range (ATR)
- MRCC 0.21
- INBX 0.94
- MACD
- MRCC -0.02
- INBX -0.21
- Stochastic Oscillator
- MRCC 23.29
- INBX 1.68
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.